Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + prednisone
- Development stage
- Phase 4
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
Bortezomib + prednisone is a combination therapy used primarily for the treatment of multiple myeloma. Bortezomib is a proteasome inhibitor that works by inhibiting the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells. Prednisone is a corticosteroid that helps reduce inflammation and suppress immune responses. This combination is often used with melphalan in what's known as the VMP regimen (Velcade, Melphalan, and Prednisone), particularly in elderly patients who are not eligible for high-dose therapy with stem cell transplantation.
02
Targets
PSMB5 (Proteasome subunit beta Type-5)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on bortezomib + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + prednisone.